Replimune (REPL) Free Cash Flow (2017 - 2026)
Replimune (REPL) posted Free Cash Flow of -$56.2 million for Q1 2026, up 14.5% sequentially from -$65.8 million in Q4 2025, and down 4.94% YoY from -$59.2 million in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Free Cash Flow (2017 - 2026) Analysis & Trends
Replimune has reported Free Cash Flow for 10 years, with the latest figure at -$56.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 4.94% year-over-year to -$56.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$280.4 million (down 45.73% YoY) and the FY2026 annual result came in at -$280.4 million, down 45.73% from the prior year.
- Free Cash Flow advanced to -$56.2 million in Q1 2026 per REPL's latest filing, from -$65.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$21.8 million in Q1 2022 and troughed at -$79.8 million in Q2 2025.
- A 5-year average of -$47.9 million and a median of -$47.3 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow climbed 5.91% in 2024, then plunged 93.13% in 2025.
- Over 5 years, Free Cash Flow stood at -$29.1 million in 2022, then sank by 61.22% to -$47.0 million in 2023, then declined by 0.6% to -$47.3 million in 2024, then plunged by 39.16% to -$65.8 million in 2025, then climbed by 14.5% to -$56.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$56.2 million, -$65.8 million, and -$78.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | -75.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -75.73 Mn |
| Mar 31, 2026 | -56.17 Mn |
| Dec 31, 2025 | -66.09 Mn |
| Sep 30, 2025 | -82.56 Mn |
| Jun 30, 2025 | -79.76 Mn |
| Mar 31, 2025 | -54.87 Mn |
| Dec 31, 2024 | -52.51 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -47.91 Mn |
| Dec 31, 2023 | -48.84 Mn |
| Sep 30, 2023 | -45.34 Mn |
| Jun 30, 2023 | -49.04 Mn |
| Mar 31, 2023 | -33.05 Mn |
| Dec 31, 2022 | -29.14 Mn |
| Sep 30, 2022 | -33.61 Mn |
| Jun 30, 2022 | -34.52 Mn |
| Mar 31, 2022 | -23.71 Mn |
| Dec 31, 2021 | -18.81 Mn |
| Sep 30, 2021 | -23.39 Mn |